Why the study?
Warfarin and other vitamin K antagonists were traditionally the sole chronic anticoagulation choices for persistent non-valvular atrial fibrillation until NOACs became available.
Does NOAC reduce thrombotic complications compared to warfarin in patients with persistent non-valvular atrial fibrillation?
Does NOAC reduce thrombotic complications compared to warfarin in patients with persistent non-valvular atrial fibrillation?
NOACs are associated with a significantly lower incidence of thrombotic complications compared to warfarin in patients with persistent non-valvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May inform NOAC selection in persistent NVAF; hypothesis-generating and requires randomized confirmation.
Background: For patients with persistent non-valvular atrial fibrillation (NVAF), chronic anticoagulation has traditionally been the mainstay of therapy. Warfarin and other vitamin K antagonists were the sole choices up until recently. Objective: To evaluate the healthcare effect and safety of patients with persistent with NVAF using Novel oral anticoagulant (NOAC) and those using warfarin group. Patients and Methods: The study consisted of 124 patients with non-rheumatic atrial fibrillation on their anticoagulation drug. Patients were classified into two main groups according to the drug used as an anticoagulant: Group I: 62 patients with non-valvular atrial fibrillation take warfarin drug 39 men and 21 women ranging in age from 40 to 75 years old. Group II: 62 patients with nonvalvular atrial fibrillation take NOAC drugs, 36 men and 25 women of varying ages 40 to 75 years. Results: Thrombotic complications:In NOAC group I: there were 5 cases of thrombotic complications per year.In Marivan group II: there were 15 cases of thrombotic complications per year.The net result showed that the incidence rate of occurrence of thrombosis among the marivan group was 25% per year compared to 8.2% in the NOAC group. There was a statistically significant difference between both groups regarding thrombotic complications. The net result showed that the incidence rate of occurrence of thrombosis among the marivan group was 20% per 6 months compared to 8.2% in the Noac group.There was a statistically significant difference between both groups regarding thrombotic complications. Conclusion: Overall evidence indicates that NOACs can be considered a safe and effective alternative to warfarin in these subgroups of patients.
No takes yet. Share an insight, caveat, or question.
Atwa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: